Cannara Biotech: From Canadian Leader to Global Supplier — The Curaleaf Catalyst
Q3 results show robust domestic growth and a strategic leap into international bulk supply with EU GMP certification on the horizon.
LOVE.TO · Earnings Call · 2026-07-15
Quarter in Review: Momentum Across Canada
Cannara Biotech delivered a strong Q3 2026, with gross cannabis revenue up 16% year-over-year to CAD 44.1 million and total net revenue of CAD 31.8 million. Adjusted EBITDA rose 11% to CAD 8.5 million, and the company generated CAD 5.7 million in operating cash flow. “The third quarter demonstrated the depth and resilience of our business.” — Nicholas Sosiak, Chief Operating Officer and Interim Chief Financial Officer · 2026-07-15 This resilience is underscored by a steady national retail market share of 4.4%, with record monthly shares in Ontario and Alberta. Quebec remains the foundation, but the revenue base is diversifying—54% of Canadian retail sales now come from outside Quebec, highlighting the success of the company's expansion strategy.The Curaleaf Deal: A Strategic Inflection Point
The most consequential development is the recently announced international supply agreement with Curaleaf, one of the world's largest cannabis companies. The two-year committed deal, worth up to CAD 21 million, marks Cannara's first long-term foray into global markets. As COO Nicholas Sosiak explained, “It's a committed term, as long as we deliver our side of the equation, which is the cannabis and supply in bulk supply as per the schedule, we'll achieve that CAD 21 million over the two years.” — Nicholas Sosiak, Chief Operating Officer and Interim Chief Financial Officer · 2026-07-15 Beyond the revenue, Curaleaf will sponsor Cannara's pursuit of EU GMP certification—a critical gateway to European medical cannabis markets. Sosiak noted the importance of this sponsorship: “In order to get EU GMP, you need to have a sponsor... This streamlines the process as nowadays, with the competition extremely high, a sponsorship is very hard to come by.” — Nicholas Sosiak, Chief Operating Officer and Interim Chief Financial Officer · 2026-07-15 The timing aligns with completion of the new processing center at Valleyfield, expected by December 2026, which will support certified production.Capacity, Innovation, and the Road to 100,000 kg
Cannara is accelerating its capacity expansion in response to visible demand. The company activated two additional grow zones in Q3, bringing total to 14 of 24, and now expects to activate four more by the end of fiscal 2027—about a year ahead of schedule. This push is driven by product innovation, particularly in high-growth segments like Flavor Bomb infused pre-rolls and the entry into the 28-gram format, which the company had previously avoided due to Price compression. Sosiak remarked on this shift: “We had previously limited our participation in this format due to significant price compression. However, with average selling prices per gram now improving, we are pursuing the opportunity from a disciplined entry point.” — Nicholas Sosiak, Chief Operating Officer and Interim Chief Financial Officer · 2026-07-15 The company also secured exclusive rights to Blue River's live rosin infusion technology, further expanding its product innovation pipeline.Financial Strength and Outlook
Cannara's balance sheet remains sturdy, with CAD 21.8 million in cash and working capital of CAD 65.1 million. The company is funding its expansion internally while maintaining profitability. As Sosiak emphasized,With a clear path to clear path to scale and a runway to 100,000 kg within its existing footprint, Cannara is positioning itself as a leading vertically integrated cannabis platform, both domestically and now internationally.We are scaling from a position of profitability and financial strength. We are expanding capacity in line with visible demand, investing behind proven brands and high-velocity products, and maintaining the operating discipline that has defined our growth.